The pace of innovation is accelerating, as three billion consumers enter the global marketplace. We are privileged to invest this fund in these exciting times. Entrepreneurs will make major improvements in health care, including in...

There’s been a dearth of innovation around infectious disease. We want more people to pay attention to this problem.

Over a three-year period we’ll look to invest the fund in roughly 40 companies across a set of industry sectors that include mobile computing, Web-enabled software, biotech, medical devices, semiconductors, and then an area that...

This is a call to action.

We’re concerned and alarmed by the lack of innovation in this area. There are very few manufacturers of vaccines today, and the plants are not distributed widely.

This new fund addresses the immediate requirement for the science, pharmaceutical, and government sectors to close significant gaps in global public health preparedness.

We will invest in companies developing fundamentally new platforms for detection, prevention and treatment of global, pathogenic infectious diseases. More than 15 million people worldwide die each year from infectious diseases. Over one third of...